News & Updates
Filter by Specialty:
DISCREET highlights apremilast potential for genital psoriasis
Individuals with psoriasis creeping into their intimate areas may find relief from apremilast, as shown by the week-32 improvements in multiple disease parameters in the phase III DISCREET study.
DISCREET highlights apremilast potential for genital psoriasis
22 Oct 2024
TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.
TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
21 Oct 2024
Real-world study supports tralokinumab for difficult-to-treat AD
Interim data from the real-world TRACE study confirm the benefits of the high-affinity monoclonal antibody tralokinumab for individuals with moderate-to-severe head and neck atopic dermatitis (H&N AD) after up to 9 months of treatment.
